Medical & Pharmacy Policy Update
Blue Cross and Blue Shield of Kansas (BCBSKS) has published the following updated medical policies on our website.
Published 12/01/23:
- Carrier Screening for Genetic Diseases
- Vyjuvek
- Bevacizumab
To view these medical policies, please visit our Medical Policy page of our website, https://www.bcbsks.com/providers/medical-policies.
The following Pharmacy Medical Policy programs will be updated January 1, 2024:
- GLP-1 Agonists
- Colony Stimulating Factors
- Injectable and Health Care Administered Oncology
- Constipation Agents
- Oral PAH
- Antidepressant
- CMV
- Winlevi
- Efgartigimod
- Relyvrio
- Oral Inhalers
- Pancreatic Enzyme
- Vyjuvek
- Bevacizumab
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have questions regarding this publication, please contact your BCBSKS provider consultant/representative.